Fore Research & Management’s Amgen AMGN Stock Holding History

Fore Research & Management’s Portfolio AMGN Stock Details AMGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-2,000	Closed	-$328K	–	47
2017 Q1	$328K	Buy	+2,000	New	+$332K	0.4%	30

Other funds holding AMGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Fore Research & Management's AMGN Position: Q2 2017 in Review

Fore Research & Management sold out of Amgen (AMGN) in Q2 2017, closing a stake of 2,000 shares — an estimated $328K sold.

Fore Research & Management first reported a position in AMGN in Q1 2017 and held it in 1 quarter. The position peaked at $328K in Q1 2017. 1,595 funds tracked by Wall St. Rank hold AMGN as of Q2 2017.

Fore Research & Management reported no remaining Amgen position as of Q2 2017 after selling out during the quarter.
Fore Research & Management sold 2,000 Amgen shares in Q2 2017, an estimated $328K.
Fore Research & Management first reported a position in Amgen in Q1 2017 and held it in 1 quarter.
Fore Research & Management's Amgen position peaked at $328K in Q1 2017.
1,595 funds tracked by Wall St. Rank held Amgen as of Q2 2017.

Based on Fore Research & Management's 13F filing for Q2 2017, filed 14 Aug 2017.